Roivant Sciences (NASDAQ:ROIV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Roivant Sciences (NASDAQ:ROIV) from a strong sell rating to a hold rating in a research report report published on Sunday.

A number of other analysts have also issued reports on ROIV. Citigroup increased their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Leerink Partners reiterated an “outperform” rating and set a $29.00 price objective on shares of Roivant Sciences in a report on Tuesday, November 11th. Guggenheim reissued a “buy” rating and set a $25.00 price objective on shares of Roivant Sciences in a research report on Friday. The Goldman Sachs Group upped their target price on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Finally, Jefferies Financial Group lifted their price target on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.56.

Roivant Sciences Trading Up 0.7%

NASDAQ:ROIV opened at $20.43 on Friday. The business’s fifty day moving average price is $17.00 and its 200 day moving average price is $13.36. The firm has a market capitalization of $13.95 billion, a price-to-earnings ratio of -36.39 and a beta of 1.23. Roivant Sciences has a 1-year low of $8.73 and a 1-year high of $21.35.

Insider Activity

In related news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $20.22, for a total transaction of $4,044,000.00. Following the completion of the transaction, the chief executive officer owned 1,504,959 shares of the company’s stock, valued at approximately $30,430,270.98. The trade was a 11.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 5,428,958 shares of company stock valued at $80,491,638 over the last 90 days. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp boosted its holdings in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Bessemer Group Inc. increased its holdings in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. CWM LLC raised its position in shares of Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its stake in shares of Roivant Sciences by 75.8% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after buying an additional 1,900 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after buying an additional 2,233 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.